About pds biotechnology corp - PDSB
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products include PDS0101 and PDS01ADC. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.
PDSB At a Glance
PDS Biotechnology Corp.
303A College Road East
Princeton, New Jersey 08540
| Phone | 1-800-208-3343 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -34,495,505.00 | |
| Sector | Health Technology | Employees | 21 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PDSB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.566 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.823 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.653 |
PDSB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,642,643.095 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PDSB Liquidity
| Current Ratio | 2.979 |
| Quick Ratio | 2.979 |
| Cash Ratio | 2.817 |
PDSB Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -90.912 |
| Return on Equity | -244.158 |
| Return on Total Capital | -131.776 |
| Return on Invested Capital | -139.991 |
PDSB Capital Structure
| Total Debt to Total Equity | 182.943 |
| Total Debt to Total Capital | 64.657 |
| Total Debt to Total Assets | 55.441 |
| Long-Term Debt to Equity | 127.10 |
| Long-Term Debt to Total Capital | 44.921 |